This inventor holds 1 USPTO granted patent. Top assignees: Hubei Wudang Animal Pharmaceutical Co., Ltd., Wuhan Academy of Agricultural Sciences. Active years: 2024.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile
Company Filing History:
Years Active: 2024
Title: Innovations of Dongqing Liu in Pharmaceutical Preparations
Introduction
Dongqing Liu is a notable inventor based in Wuhan, China. He has made significant contributions to the field of pharmaceutical preparations, particularly through his innovative work on arctigenin liquid nano-preparation.
Latest Patents
Dongqing Liu holds a patent for an arctigenin liquid nano-preparation and its preparation method. This patent addresses the technical field of pharmaceutical preparation. The arctigenin is transformed into a liquid nano-preparation, which boasts advantages such as a nanoscale droplet diameter, significantly increased specific surface area, rapid absorption, and high bioavailability. Furthermore, the nano-preparation can be captured by wandering leucocytes, allowing for targeted drug delivery to inflammatory lesions through chemiotaxis. This innovation enhances the therapeutic efficacy of arctigenin.
Career Highlights
Throughout his career, Dongqing Liu has worked with esteemed organizations such as the Wuhan Academy of Agricultural Sciences and Hubei Wudang Animal Pharmaceutical Co., Ltd. His experience in these institutions has contributed to his expertise in pharmaceutical innovations.
Collaborations
Dongqing Liu has collaborated with notable colleagues, including Bin He and Lijun Wu. Their joint efforts have further advanced the research and development of pharmaceutical preparations.
Conclusion
Dongqing Liu's contributions to the field of pharmaceutical preparations, particularly through his patented arctigenin liquid nano-preparation, highlight his innovative spirit and dedication to advancing medical science. His work continues to influence the development of targeted therapies.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile